NCT03525821View on ClinicalTrials.gov

Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED)

PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

September 13, 2020

Study Completion Date

September 13, 2020

Conditions
Fractures, Closed
Interventions
DRUG

Ketamine Hydrochloride

intranasal use of ketamine 1mg/kg with nitrous oxide

Trial Locations (1)

06200

Hôpitaux pédiatriques de Nice CHU-Lenval, Nice

All Listed Sponsors
lead

Fondation Lenval

OTHER

NCT03525821 - Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED) | Biotech Hunter | Biotech Hunter